Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy KemPharm (KMPH) stocks in Canada

Learn how to easily invest in KemPharm stocks.

KemPharm is a biotechnology business based in the US. KemPharm stocks (KMPH.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $15 – a decrease of 4.78% over the previous week. KemPharm employs 22 staff and has a trailing 12-month revenue of around $28.4 million.

How to buy shares in KemPharm

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – KMPH – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

KemPharm stock price (NASDAQ:KMPH)

Use our graph to track the performance of KMPH stocks over time.

KemPharm shares at a glance

Information last updated 2022-01-25.
Latest market close$6.17
52-week range$5.86 - $18.15
50-day moving average $8.38
200-day moving average $9.79
Wall St. target price$19.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-2.95

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
Wealthsimple Trade
Finder Rating:
3.9 / 5
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
3.8 / 5
$4.99 - $9.99
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
4.1 / 5
Min. $1.00, Max. 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
CIBC Investor's Edge
Finder Rating:
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get up to $5,000 cash back. Conditions apply. Offer ends March 1, 2022.

Compare up to 4 providers

Online stock trading

Is it a good time to buy KemPharm stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

KemPharm price performance over time

Historical closes compared with the close of $6.17 from 2022-01-27

1 week (2022-01-20) -12.23%
1 month (2021-12-27) -33.73%
3 months (2021-10-25) N/A
6 months (2021-07-29) -40.16%
1 year (2021-01-29) 2.32%
2 years (2020-01-29) 1,414.11%
3 years (2019-01-29) 127.68%
5 years (2017-01-27) 73.80%

Is KemPharm under- or over-valued?

Valuing KemPharm stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of KemPharm's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

KemPharm's EBITDA

KemPharm's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $7.6 million.

The EBITDA is a measure of a KemPharm's overall financial performance and is widely used to measure a its profitability.

KemPharm financials

Revenue TTM $28.4 million
Operating margin TTM 25.87%
Gross profit TTM $12 million
Return on assets TTM 6.2%
Return on equity TTM -30.85%
Profit margin -37.66%
Book value $3.73
Market capitalisation $234.9 million

TTM: trailing 12 months

KemPharm share dividends

We're not expecting KemPharm to pay a dividend over the next 12 months.

Have KemPharm's shares ever split?

KemPharm's shares were split on a 1:16 basis on 28 December 2020. So if you had owned 16 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your KemPharm shares – just the quantity. However, indirectly, the new 1500% higher share price could have impacted the market appetite for KemPharm shares which in turn could have impacted KemPharm's share price.

KemPharm share price volatility

Over the last 12 months, KemPharm's shares have ranged in value from as little as $5.86 up to $18.15. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while KemPharm's is 3.1485. This would suggest that KemPharm's shares are significantly more volatile than the average for this exchange and represent a higher risk.

KemPharm overview

KemPharm, Inc. , a specialty pharmaceutical company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. Its prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, stimulant use disorder, and CNS rare diseases, including idiopathic hypersomnia. KemPharm's lead clinical development candidate for the treatment of stimulant use disorder, KP879, is based on its prodrug of d-methylphenidate, known as serdexmethylphnidate. In addition, the company has received FDA approval for AZSTARYS, a new once-daily treatment for attention deficit hyperactivity disorder in patents age six years and older, and for APADAZ, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen. KemPharm, Inc.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site